Business Context and Reporting Period
Company: Ionis Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Ionis is a fully integrated commercial-stage biotechnology company and a pioneer in RNA-targeted medicines. The company has transitioned from a development-focused entity to one with independent commercial operations, currently marketing seven medicines (TRYNGOLZA, DAWNZERA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA) and maintaining a robust pipeline in neurology, cardiometabolic diseases, and rare diseases.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $943.7 | $705.1 |
| Commercial Revenue | $435.8 | $293.1 |
| R&D Revenue | $507.9 | $412.0 |
| Total Operating Expenses | $1,325.4 | $1,180.2 |
| Loss from Operations | $(381.7) | $(475.1) |
| Net Loss | $(381.4) | $(453.9) |
| Cash, Cash Equivalents & Short-Term Investments | $2,677.4 | $2,297.7 |
| Stockholders' Equity | $489.1 | $588.4 |
Revenue Composition: Commercial revenue increased 49% year-over-year, driven by the launch of TRYNGOLZA ($107.5M) and DAWNZERA ($7.8M), alongside higher royalty revenue from SPINRAZA ($212.3M) and WAINUA ($49.1M). R&D revenue grew due to a $280M upfront payment from Ono Pharmaceutical for the sapablursen license.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $238.6 million (34%) compared to 2024. This was primarily driven by the initiation of independent product sales for TRYNGOLZA and DAWNZERA and significant collaboration milestones.
- Operating Expenses: Total operating expenses increased by $145.2 million (12%). Selling, General, and Administrative (SG&A) expenses rose significantly ($393.9M vs. $267.5M) due to the costs associated with launching TRYNGOLZA, DAWNZERA, and WAINUA.
- Net Loss Improvement: Net loss decreased by $72.5 million (16%) to $381.4 million, reflecting revenue growth outpacing expense increases.
- Debt Structure: In November 2025, the company issued $770.0 million in 0% Convertible Senior Notes due 2030. Proceeds were used to repurchase $200.0 million of 0% Notes due 2026, resulting in a $16.3 million induced conversion expense.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Upcoming Launches: The company anticipates launching olezarsen for severe hypertriglyceridemia (sHTG) in mid-2026 following FDA priority review (PDUFA date June 30, 2026) and zilganersen for Alexander disease in the second half of 2026.
- Commercial Expansion: Ionis is scaling its independent commercial infrastructure to support the rollout of TRYNGOLZA, DAWNZERA, and future launches.
- Partnerships: Key collaborations include AstraZeneca (WAINUA), Biogen (SPINRAZA, QALSODY), and Ono (sapablursen).
Risks and Contingencies
- Commercialization Risk: Limited experience in independent commercialization poses risks regarding sales infrastructure efficiency and market acceptance.
- Regulatory Risk: Continued approval for QALSODY is contingent on confirmatory trials; olezarsen and zilganersen approvals are pending.
- Competition: Significant competition exists in key therapeutic areas, including FCS (Arrowhead's plozasiran), HAE (multiple approved therapies), and ATTR (Alnylam, Pfizer).
- Legal Proceedings: Ongoing patent litigation with Arrowhead Pharmaceuticals regarding ApoC-III inhibitors (plozasiran vs. TRYNGOLZA).
- Reimbursement: Potential impact of U.S. healthcare reform, including the Inflation Reduction Act and proposed "most favored nation" pricing models.
Investor Verification Checklist
- Commercial Execution: Verify the trajectory of TRYNGOLZA and DAWNZERA sales against internal targets to assess the scalability of the new commercial organization.
- Regulatory Milestones: Monitor the FDA decision on olezarsen for sHTG (PDUFA June 30, 2026) and the NDA submission status for zilganersen.
- Patent Litigation: Track the outcome of the patent infringement lawsuit against Arrowhead Pharmaceuticals, which could impact the exclusivity of the FCS franchise.
- Debt Maturity: Confirm the settlement plan for the remaining $432.5 million of 0% Notes due 2026, which mature in April 2026.
- Partnership Milestones: Review upcoming milestone triggers with AstraZeneca (WAINUA ATTR-CM approval) and Ono (sapablursen pivotal trial initiation).